Hdm1005

1 study on Hdm1005 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on Hdm1005. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

Hdm1005 studies and clinical research

2026-05-14 PubMed · preclinical animal · n preclinical

HDM1005 (poterepatide), a novel GLP-1/GIP dual agonist, achieves superior HbA1c reduction and weight loss over Tirzepatide.

This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…

Research tools

Free, no account — handy when you're working with Hdm1005.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$14 monthly or $88/year

Create an account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

Hdm1005 studies and clinical research

HDM1005 (poterepatide), a novel GLP-1/GIP dual agonist, achieves superior HbA1c reduction and weight loss over Tirzepatide.

Research tools